Related Experiment Video
Updated: Sep 7, 2026

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations
Published on: January 10, 2015
Tobacco Industry's Corporate Diversification in the Evolving Landscape of Tobacco Control Laws in India - A
Anwita Khaitan1, Shivam Kapoor2, Amit Yadav3
1Department of Community Medicine, Central Armed Police Forces Institute of Medical Sciences (CAPFIMS) Centre, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Background:
India has established a strong policy framework to curb tobacco use-a significant risk factor for noncommunicable diseases (NCDs)-by enforcing Cigarettes and Other Tobacco Products Act (COTPA) 2003 and ratifying WHO-Framework Convention on Tobacco Control (WHO-FCTC) 2003. Within this regulatory context, India's tobacco companies have diversified business activities and adopted brand extension and other promotional strategies. This exploratory study examines these diversification and surrogate marketing practices and their relevance to tobacco control policy implementation and NCD prevention in India.
Methodology:
A historical review and secondary data analysis were conducted using company reports, academic literature, and industry sources. Six tobacco companies-ITC Limited, Godfrey Phillips India Ltd. (GPI), DS Group, Pataka, Miraj, and Mangalore Ganesh Beedi Works-were analyzed for diversification timelines, brand strategies, and regulatory responses. Qualitative analyses and time-series mapping were undertaken.
Results:
ITC Limited emphasized brand stretching using its Wills ® brand (Wills ® Lifestyle, Wills® India Fashion Week), while GPI used its Red and White ® brand (Red and White ® Bravery Awards). DS Group diversified into fast-moving consumer goods (FMCG) and hospitality, with Rajnigandha ® as its flagship brand. Pataka and Miraj expanded into pan masala and FMCG sectors. Ganesh Beedi, however, remained tobacco-centric, relying on scale and cultural imagery. These strategies circumvented COTPA's advertising restrictions and contravened WHO-FCTC Article 13.
Conclusions:
Brand extension and surrogate marketing have sustained tobacco brand visibility within the current regulatory framework. Enforcing COTPA and WHO-FCTC Article 13 with more transparent oversight of corporate diversification may effectively restrict tobacco advertising, promotion, and sponsorship and strengthen NCD prevention.
Related Concept Videos
Drug Control Governance: Regulatory Bodies and Their Impact
Drug Regulation
Statistical Methods for Analyzing Epidemiological Data
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
